A FAR

- ≤0.079
- >0.079
- ≤0.079-censored
- >0.079-censored

P = 0.001

B MLR

- ≤0.36
- >0.36
- ≤0.36-censored
- >0.36-censored

P < 0.001

with agressive treatments

No. at risk

≤ 0.079	116	32	6	0	0
> 0.079	123	19	2	0	0

No. at risk

≤ 0.36	138	40	8	0	0
> 0.36	101	11	0	0	0

C NLR

- ≤2.61
- >2.61
- ≤2.61-censored
- >2.61-censored

P < 0.001

D PLR

- ≤170.73
- >170.73
- ≤170.73-censored
- >170.73-censored

P < 0.001

with agressive treatments

No. at risk

≤ 2.61	78	28	6	0	0
> 2.61	161	23	2	0	0

No. at risk

≤ 170.73	179	45	8	0	0
> 170.73	60	6	0	0	0

E FAR

- ≤0.079
- >0.079
- ≤0.079-censored
- >0.079-censored

P < 0.001

F MLR

- ≤0.36
- >0.36
- ≤0.36-censored
- >0.36-censored

P = 0.015

without agressive treatments

No. at risk

≤ 0.079	122	41	7	0	0
> 0.079	173	20	6	1	0

No. at risk

≤ 0.36	157	38	8	1	0
> 0.36	138	23	5	0	0

No. at risk						No. at risk					
≤ 2.61	97	25	7	1	0	≤ 170.73	193	43	9	1	0
> 2.61	198	36	6	0	0	> 170.73	102	18	4	0	0

S10 Fig. Kaplan-Meier survival curves of different locally advanced or metastatic pancreatic cancer patients subgroups in training set. (A) Data compares fibrinogen-to-albumin ratio (FAR) ≤ 0.079 vs. > 0.079 (p=0.001) in patients who receive aggressive treatments. (B) Data compares monocyte-to-lymphocyte ratio (MLR) ≤ 0.36 vs. > 0.36 (p < 0.001) in patients who receive aggressive treatments. (C) Data compares neutrophil to lymphocyte ratio (NLR) ≤ 2.61 vs. > 2.61 (p < 0.001) in patients who receive aggressive treatments. (D) Data compares platelet-to-lymphocyte ratio (PLR) ≤ 170.73 vs. > 170.73 (p < 0.001) in patients who receive aggressive treatments. (E) Data compares FAR ≤ 0.079 vs. > 0.079 (p < 0.001) in patients who did not receive aggressive treatments. (F) Data compares MLR ≤ 0.36 vs. > 0.36 (p=0.015) in patients who did not receive aggressive treatments. (G) Data compares NLR ≤ 2.61 vs. > 2.61 (p < 0.004) in patients who did not receive aggressive treatments. (H) Data compares PLR ≤ 170.73 vs. > 170.73 (p > 0.05) in patients who did not receive aggressive treatments.